Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
Publication
, Journal Article
Giordano, SH; Freedman, RA; Somerfield, MR; Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel
Published in: J Clin Oncol
January 20, 2022
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Duke Scholars
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
January 20, 2022
Volume
40
Issue
3
Start / End Page
307 / 309
Location
United States
Related Subject Headings
- Time Factors
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Neoplasm Staging
- Medical Oncology
- Humans
- Female
- Disease-Free Survival
- Consensus
- Chemotherapy, Adjuvant
Citation
APA
Chicago
ICMJE
MLA
NLM
Giordano, S. H., Freedman, R. A., Somerfield, M. R., & Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. (2022). Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. J Clin Oncol, 40(3), 307–309. https://doi.org/10.1200/JCO.21.02677
Giordano, Sharon H., Rachel A. Freedman, Mark R. Somerfield, and Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. “Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.” J Clin Oncol 40, no. 3 (January 20, 2022): 307–9. https://doi.org/10.1200/JCO.21.02677.
Giordano SH, Freedman RA, Somerfield MR, Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. J Clin Oncol. 2022 Jan 20;40(3):307–9.
Giordano, Sharon H., et al. “Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.” J Clin Oncol, vol. 40, no. 3, Jan. 2022, pp. 307–09. Pubmed, doi:10.1200/JCO.21.02677.
Giordano SH, Freedman RA, Somerfield MR, Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. J Clin Oncol. 2022 Jan 20;40(3):307–309.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
January 20, 2022
Volume
40
Issue
3
Start / End Page
307 / 309
Location
United States
Related Subject Headings
- Time Factors
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Neoplasm Staging
- Medical Oncology
- Humans
- Female
- Disease-Free Survival
- Consensus
- Chemotherapy, Adjuvant